US · OKYO
OKYO Pharma Limited
- Sector
- Healthcare · Biotechnology
- Headquarters
- London W1K 1NA
- Website
- okyopharma.com
Price · as of 2025-03-31
$1.66
Market cap 69.35M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | $2.09 | ||||
| 2023 | $1.31 | ||||
| 2024 | $1.27 | ||||
| 2025 | $1.90 |
AI valuation
Our deep-learning model estimates OKYO Pharma Limited's (OKYO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $1.66
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| OKYO | OKYO Pharma Limited | $1.66 | 69.35M | — | — | — | — | -9.41 | -13.52 | — | -10.37 | -0.05 | -13.52 | 0.00% | — | — | 139.47% | 61.45% | -305.45% | 0.00 | -8.14 | 0.40 | 0.37 | 0.22 | 1990000.00% | — | -8091.00% | -2.42% | -0.20 | 26.23% | 0.00% | 0.00% | 0.98% | -10.22 | -40.54 | — | -57.84 |
| ANEB | Anebulo Pharmaceuticals, … | $0.36 | 14.68M | — | — | — | — | -9.49 | 6.90 | — | -8.50 | — | 6.90 | 0.00% | — | — | -109.69% | -2464.82% | -104.63% | 0.00 | -24.14 | 53.36 | 52.20 | 1.44 | -2188.00% | — | -2152.00% | -7.89% | -28.32 | -1696.85% | 0.00% | 0.00% | 10.60% | -7.47 | -10.85 | — | 89.17 |
| CLNN | Clene Inc. | $5.23 | 48.62M | +633% | -65% | — | +3,976% | -0.81 | -3.60 | 93.13 | -1.20 | — | -3.60 | 79.53% | -9676.32% | -11520.47% | -1738.36% | -637.51% | -98.90% | -2.35 | -8.14 | 1.57 | 1.22 | -0.26 | -3987.00% | -4771.00% | -3003.00% | -67.00% | -2.07 | -411.12% | 0.00% | 0.00% | 0.00% | -1.22 | -1.90 | 118.53 | -17.65 |
| COYA | Coya Therapeutics, Inc. | $4.96 | 82.41M | +515% | -78% | — | +508% | -7.05 | 2.65 | 29.50 | -3.87 | -29.29 | 2.65 | -233.86% | -485.35% | -418.70% | -39.57% | -774.97% | -34.76% | 0.00 | — | 11.59 | 10.22 | 2.23 | 2405.00% | -4079.00% | -804.00% | -9.81% | -2.69 | -484.62% | 0.00% | 0.00% | 5.45% | -3.86 | -6.46 | 18.71 | 11.79 |
| IMMX | Immix Biopharma, Inc. | $8.07 | 270.94M | — | — | — | — | -1.99 | 3.24 | — | -1.17 | — | 3.24 | 0.00% | — | — | -145.76% | 1016.65% | -100.83% | 0.08 | — | 2.33 | 2.26 | 0.74 | -1461.00% | — | 3807.00% | -36.69% | -1.68 | 707.20% | 0.00% | 0.00% | 0.00% | -1.16 | -1.67 | — | -4.58 |
| MGNX | MacroGenics, Inc. | $1.99 | 125.88M | +1,648% | -54% | — | — | -2.12 | 1.22 | 0.96 | 0.38 | -0.35 | 1.22 | 91.71% | -74.54% | -45.14% | -49.85% | 242.04% | -23.91% | 0.32 | -99.17 | 3.92 | 3.71 | 2.53 | 61333.00% | 15937.00% | -987.00% | -50.71% | -1.23 | 157.77% | 0.00% | 0.00% | 55.15% | 0.20 | 0.31 | -0.15 | -5.76 |
| PLRX | Pliant Therapeutics, Inc. | $1.30 | 79.88M | +1,747% | — | — | — | -0.47 | 0.32 | — | 0.96 | -1.78 | 0.32 | 0.00% | — | — | -54.09% | 61060.16% | -46.27% | 0.20 | -75.52 | 10.91 | 10.78 | 0.05 | 2618.00% | -10000.00% | 3587.00% | -162.48% | -4.68 | 42607.22% | 0.00% | 0.00% | 0.00% | 0.86 | 1.24 | — | -2.77 |
| SLGL | Sol-Gel Technologies Ltd. | $91.68 | 255.4M | +7% | -70% | — | — | -15.01 | 5.50 | 13.76 | -13.16 | — | 5.50 | 97.98% | -104.13% | -91.70% | -31.35% | -281.59% | -26.08% | 0.05 | — | 5.92 | 5.21 | 1.76 | -6238.00% | 64247.00% | -2224.00% | -8.75% | -2.63 | -325.58% | 0.00% | 0.00% | 7.76% | -11.33 | -9.80 | 11.80 | 4.69 |
| TLSA | Tiziana Life Sciences Ltd | $1.45 | 86.17M | — | — | — | — | -9.51 | 22.90 | — | -5.21 | — | 22.90 | 0.00% | — | — | -200.16% | -455.01% | -80.79% | 0.03 | -2632.33 | 1.02 | 1.01 | 0.22 | -3529.00% | — | -9006.00% | -1.37% | -0.17 | -50.21% | 0.00% | 0.00% | 2.98% | -5.48 | -70.08 | — | -15.21 |
| WHWK | Whitehawk Therapeutics In… | $3.51 | 165.42M | +472% | -63% | — | — | -0.90 | 1.09 | 2.21 | -0.17 | — | 1.09 | -108.04% | -259.62% | -245.13% | -80.79% | -3655.27% | -62.83% | 0.02 | -438.04 | 3.59 | 3.11 | 0.43 | -328.00% | 669.00% | -382.00% | -106.81% | -3.49 | -3316.39% | 0.00% | 0.00% | 0.00% | -0.16 | -0.18 | 0.42 | -6.74 |
| ZNTL | Zentalis Pharmaceuticals,… | $2.39 | 172.68M | — | -34% | — | — | -0.78 | 0.38 | 1.92 | 1.07 | — | 0.38 | 100.00% | -283.57% | -245.96% | -42.83% | -4301.81% | -33.43% | 0.13 | — | 7.32 | 7.13 | -0.05 | -4787.00% | — | -1791.00% | -132.25% | -3.24 | -3849.27% | 0.00% | 0.00% | 6.95% | 1.04 | 1.16 | -2.95 | -2.98 |
About OKYO Pharma Limited
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
- CEO
- Robert J. Dempsey
- Employees
- 3
- Beta
- -0.23
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.66) − 1 = — (DCF, example).